MX2020013567A - Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes. - Google Patents

Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.

Info

Publication number
MX2020013567A
MX2020013567A MX2020013567A MX2020013567A MX2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A
Authority
MX
Mexico
Prior art keywords
film
diabetes
treatment
coated tablet
triazine derivative
Prior art date
Application number
MX2020013567A
Other languages
English (en)
Inventor
Sébastien Bolze
Maxime Laugier
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of MX2020013567A publication Critical patent/MX2020013567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a una tableta recubierta con película que comprende un núcleo interno y un recubrimiento externo, en el que el núcleo interno comprende una alta proporción de un derivado de triazina específico, a saber, 2-amino-3,6-dihidro-4-di metilamino-6-metil-1,3,5-triazina y sus sales farmacéuticamente aceptables, y un aglutinante específico. También se dirige al uso de estas tabletas en el tratamiento de la diabetes y/o sus complicaciones. Esta invención se dirige además a un proceso específico para la fabricación de estas tabletas recubiertos con película, que implica una etapa de granulación en un mezclador de alto cizallamiento.
MX2020013567A 2018-06-14 2019-06-11 Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes. MX2020013567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305730 2018-06-14
PCT/EP2019/065158 WO2019238647A1 (en) 2018-06-14 2019-06-11 Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2020013567A true MX2020013567A (es) 2021-05-27

Family

ID=62778848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013567A MX2020013567A (es) 2018-06-14 2019-06-11 Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.

Country Status (13)

Country Link
US (1) US11813362B2 (es)
EP (1) EP3806828A1 (es)
JP (1) JP7266616B2 (es)
KR (1) KR20210003786A (es)
CN (1) CN112218623A (es)
AU (1) AU2019286326A1 (es)
BR (1) BR112020025112A2 (es)
CA (1) CA3103324A1 (es)
IL (1) IL279299A (es)
MX (1) MX2020013567A (es)
PH (1) PH12020551741A1 (es)
SG (1) SG11202010322XA (es)
WO (1) WO2019238647A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021117861A1 (ja) * 2019-12-13 2021-06-17 大日本住友製薬株式会社 製造性及び溶出性に優れた小型錠剤
KR20230091684A (ko) * 2021-12-16 2023-06-23 주식회사 종근당 다파글리플로진과 시타글립틴을 포함하며, 정제사이즈 축소를 통해 복용편의성이 향상된 약제학적 복합제제 및 이의 제조방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
DE69814151T2 (de) 1997-12-12 2004-03-25 Abbott Laboratories, Abbott Park Triazin angiogenese-inhibitoren
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
CN100451008C (zh) 2004-01-20 2009-01-14 默克公司 抗糖尿病的唑烷二酮类和噻唑烷二酮类
DE602006014840D1 (de) 2005-08-11 2010-07-22 Sru Biosystems Inc Beugungsbasierter sensor, der markierungsfreie bindungserkennung und fluoreszenz-verstärkung kombiniert
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
WO2008069222A1 (en) 2006-12-05 2008-06-12 Semiconductor Energy Laboratory Co., Ltd. Plasma display panel and field emission display
DE102007054416A1 (de) 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
HUE027532T2 (en) 2008-05-23 2016-10-28 Poxel Sas Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives
CN102112425B (zh) 2008-07-29 2014-06-11 普克塞尔公司 通过控制粒径的结晶从对映体混合物中分离对映体组分的方法
KR101623819B1 (ko) 2008-12-12 2016-05-24 뽁셀 에스아에스 트리아진 유도체들과 인슐린의 조합물 및 당뇨병을 치료하기 위한 이의 용도
JP5485292B2 (ja) 2008-12-12 2014-05-07 ポクセル・エスアーエス Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
CN105147662A (zh) * 2009-02-13 2015-12-16 贝林格尔·英格海姆国际有限公司 包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物及其药物剂型、制备方法与用途
EP2411375B1 (en) 2009-03-26 2013-08-28 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
EP2579879B1 (en) 2010-06-09 2016-03-23 Poxel Triazine derivatives for delaying the onset of type 1 diabetes
WO2012072663A1 (en) 2010-12-01 2012-06-07 Poxel Separation of triazine derivatives enantiomers using tartaric acid
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
WO2014160524A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Cardio- metabolic and cascular effects of glp-1 metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP3217987A4 (en) 2014-11-10 2018-06-20 Merck Sharp & Dohme Corp. Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
CN105990398B (zh) 2015-02-16 2019-01-11 上海和辉光电有限公司 有机发光二极管显示器及其制造方法
JP7161405B2 (ja) 2016-03-16 2022-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エンパグリフロジンを含む医薬組成物及びその使用
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
CN111918655B (zh) 2018-06-06 2024-05-31 博希尔公司 治疗患有慢性肾脏疾病的糖尿病受试者的方法

Also Published As

Publication number Publication date
WO2019238647A1 (en) 2019-12-19
BR112020025112A2 (pt) 2021-03-23
CA3103324A1 (en) 2019-12-19
KR20210003786A (ko) 2021-01-12
AU2019286326A1 (en) 2020-12-10
SG11202010322XA (en) 2020-11-27
US11813362B2 (en) 2023-11-14
JP2021526506A (ja) 2021-10-07
US20210212951A1 (en) 2021-07-15
JP7266616B2 (ja) 2023-04-28
EP3806828A1 (en) 2021-04-21
CN112218623A (zh) 2021-01-12
PH12020551741A1 (en) 2021-06-07
IL279299A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
MX2023001689A (es) Inhibidores de bcl-2.
SG11201907038WA (en) Quinazoline compound
PH12021551019A1 (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
SA519401336B1 (ar) تركيبة صيدلية
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
MX2019005009A (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
MX2019004113A (es) Compuestos farmaceuticos.
MX2016006564A (es) Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
PH12020551741A1 (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MX2020013162A (es) Comprimidos de liberacion inmediata que contienen un farmaco y procesos para formar los comprimidos.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2022001535A (es) Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.
MX2021003033A (es) Formulaciones de compuestos de cicloserina y aplicaciones de estas.
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
PH12021550572A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
MX2022005991A (es) Farmaco combinado.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها